Bayer with continued strong performance

08

November

2022

Summary

Group sales increase by 5.7 percent (Fx & portfolio adj.) to 11.281 billion euros  / EBITDA before special items rises by 17.3 percent to 2.451 billion euros / Crop Science achieves strong sales gains – sales also up at Pharmaceuticals and Consumer Health / All divisions report significant increase in earnings / Core earnings per share climb by 7.6 percent to 1.13 euros / Net income at 546 million euros / Free cash flow at 1.738 billion euros / Major progress in Pharmaceuticals pipeline / Full-year Group outlook confirmed